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BRCA1/2-mutated ovarian cancers (OCs) are defec-
tive in homologous recombination repair (HRR) of
double-strand breaks (DSBs) and thereby sensitive
to platinum and PARP inhibitors (PARPis). Multiple
PARPis have recently received US Food and Drug
Administration (FDA) approval for treatment of
OCs, and resistance to PARPis is a major clinical
problem. Utilizing primary and recurrent BRCA1/2-
mutated carcinomas from OC patients, patient-
derived lines, and an in vivo BRCA2-mutated mouse
model, we identified a microRNA, miR-493-5p, that
induced platinum/PARPi resistance exclusively in
BRCA2-mutated carcinomas. However, in contrast
to the most prevalent resistance mechanisms in
BRCA mutant carcinomas, miR-493-5p did not
restore HRR. Expression of miR-493-5p in BRCA2-
mutated/depleted cells reduced levels of nucleases
and other factors involved in maintaining genomic
stability. This resulted in relatively stable repli-
cation forks, diminished single-strand annealing
of DSBs, and increased R-loop formation. We
conclude that impact of miR-493-5p on multiple
pathways pertinent to genome stability cumulatively
causes PARPi/platinum resistance in BRCA2mutant
carcinomas.INTRODUCTION
Large-scale genomic studies have demonstrated that approxi-
mately 50%of high-grade serous ovarian carcinomas (HGSOCs)
harbor genetic and/or epigenetic alterations in homologous
recombination repair (HRR) pathway genes (Cancer Genome100 Cell Reports 23, 100–111, April 3, 2018 ª 2018 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://Atlas Research Network, 2011), most commonly in BRCA1 and
BRCA2 (Konstantinopoulos et al., 2015; Lord and Ashworth,
2016). Loss of HRR causes genomic instability, hyper-depen-
dence on alternative DNA repair mechanisms, and enhanced
sensitivity to certain types of DNA-damaging chemotherapy,
such as platinum analogs and topoisomerase inhibitors (Evers
et al., 2010; Konstantinopoulos et al., 2015). HRR-deficient can-
cers are also exquisitely sensitive to PARP inhibitors (PARPis),
which exhibit synthetic lethality to cells with defective HRR.
This synthetic lethal interaction is being exploited therapeutically
in ovarian carcinoma whereby three PARPis, i.e., olaparib, ruca-
parib, and niraparib, have received US Food and Drug Adminis-
tration (FDA) approval as monotherapy in patients with germline
or somatic BRCA1/2 mutations or as maintenance therapy after
platinum chemotherapy in platinum-sensitive recurrent ovarian
carcinoma (Konstantinopoulos et al., 2015; Matulonis et al.,
2016; Mirza et al., 2016; Swisher et al., 2017). The efficacy of
PARPis against HRR-deficient cells can be explained by several
mechanisms, including inhibition of base excision repair (BER),
trapping of PARP-DNA complexes at the replication fork,
enhancement of toxic classic non-homologous end joining
(NHEJ), and inhibition of PARP1/Polq-mediated alternative end
joining (alt-EJ) (Konstantinopoulos et al., 2015).
Despite their predicted synthetic lethality, a large fraction of
carcinomas eventually become resistant to these therapies.
Underlying HRR deficiency is important for the cytotoxicity of
PARPis and platinum agents, and this is highlighted by the fact
that the most prevalent mechanisms of resistance to these ther-
apies are secondary somatic BRCA1/2 mutations that restore
the open reading frame and re-establish HRR proficiency (Sakai
et al., 2008; Swisher et al., 2008). Besides reversion mutations,
there are few clinically relevant mechanisms that have been
identified. In BRCA1-mutated carcinomas, PARPi and platinum
resistance may also occur via suppression of NHEJ, which
also restores HRR proficiency. Loss of NHEJ confers resistance
only to BRCA1 mutant carcinomas as BRCA1 is required in the
early steps of HRR, and it may be ‘‘bypassed’’ either by loss ofcreativecommons.org/licenses/by-nc-nd/4.0/).
53BP1 or loss of REV7 or via downregulation of the Ku70/Ku80
complex, which has been shown to restore competent HRR in
BRCA1-deficient cells (Aly and Ganesan, 2011; Bouwman
et al., 2010; Bunting et al., 2010; Xu et al., 2015). Identifying
the mechanism of platinum and PARPi resistance in BRCA2-
mutated carcinomas has been a challenge as HRR is not
restored in cells expressingmutantBRCA2. However, few recent
studies have revealed that BRCA2mutant carcinomas might still
develop platinum and PARPi resistance without restoration of
HRR proficiency via a complex mechanism where stalled DNA
replication fork is protected from degradation by nucleases by
downregulation of proteins such as PTIP, CHD4, or EZH2 (Guil-
lemette et al., 2015; Lai et al., 2017; Patch et al., 2015; Ray
Chaudhuri et al., 2016; Rondinelli et al., 2017). Importantly, it is
not clear how these factors would be downregulated in BRCA2
mutant cancers.
We have been systematically studying the role of microRNAs
(miRNAs) in HRR and their role in mediating PARPi sensitivity
(Choi et al., 2014, 2016; Moskwa et al., 2011). In this regard, us-
ing a candidate-based approach, we have recently shown that
overexpression of a miRNA, miR-622, induces resistance to
PARPi and platinum-based drugs in BRCA1mutant ovarian car-
cinomas (Choi et al., 2016). We observed that miR-622 regulated
the expression of the Ku complex and suppressed NHEJ,
thereby rescuing the HRR deficiency of BRCA1 mutant ovarian
carcinomas and induced resistance to PARPi and platinum-
based drugs.
To systematically identify clinically relevant miRNAs that
mediate platinum and PARPi resistance in BRCA1/2-mutated
cancers, we performed next-generation sequencing of small
RNAs extracted from the tumors of 38 patients with primary
and recurrent BRCA1/2-mutated ovarian carcinomas. The re-
sults of the small RNA sequencing were independently validated
in The Cancer Genome Atlas (TCGA) dataset and revealed a
miRNA, miR-493-5p, as a mediator of resistance to platinum
and PARPis exclusively in BRCA2-mutated ovarian carcinomas.
We have characterized the functional impact of miR-493-5p
in BRCA2-mutated cancer cells and demonstrated that it in-
duces platinum and PARPi resistance by influencing multiple
genome-stabilizing pathways that include single-strand anneal-
ing (SSA), R-loops, and replication fork stability.
RESULTS
Small RNA Sequencing of BRCA1/2-Mutated Ovarian
Carcinomas Identifies Several miRNAs as Possible
Mediators of Platinum Resistance
We performed next-generation sequencing of small RNAs ex-
tracted from the tumors of 38 patients with primary and recurrent
BRCA1/2-mutated ovarian carcinomas. None of these carci-
nomas harbored BRCA1/2 reversion mutations, as we wanted
to focus on mechanisms of resistance that were unrelated
to secondary BRCA1/2 mutations. Our analysis focused on
miRNAs that fulfilled two criteria: (1) were differentially expressed
between platinum-resistant/refractory and platinum-sensitive
BRCA1/2-mutated carcinomas and (2) their expression was
concordantly associated with outcome after platinum therapy
among BRCA1/2-mutated carcinomas.Eight miRNAs, miR-139-5p, miR-493-5p, miR-378a-5p and
miR-491-5p, miR-5000-3p, miR-369-3p, miR-3188, and miR-
141-3p were identified to fulfill these criteria. Five of these
miRNAs, miR-139-5p, miR-493-5p, miR-3188, miR-369-3p,
and miR-5000-3p were overexpressed (p < 0.05) in platinum-
resistant/refractory BRCA1/2-mutated carcinomas compared
to platinum-sensitive BRCA1/2-mutated carcinomas and were
associated with worse outcome after platinum therapy (Figures
1A and S1A). Conversely, the other three miRNAs, miR-141-
3p, miR-378a-5p, and miR-491-5p, were under-expressed
(p < 0.05) in platinum-resistant/refractory BRCA1/2-mutated
carcinomas compared to platinum-sensitive BRCA1/2-mutated
carcinomas and were associated with better outcome after plat-
inum therapy (Figures 1A and S1A).
We then explored whether the impact of each of these 8
miRNAs was specific for BRCA1- or BRCA2-mutated carci-
nomas. Strikingly, the effect of miR-493-5p (Figure 1B) and
miR-491-5p (Figure S1B) on outcome was only evident in
BRCA2-mutated carcinomas, whereas the effect of miR-378a-
5p, miR-3188, and miR-141-3p was evident only in BRCA1-
mutated carcinomas (Figure S1B). Effect of miR-5000-3p,
miR-139-5p, and miR-369-3p was not specific for BRCA1- or
BRCA2-mutated carcinomas (Figure S1B).
Independent Validation of Small RNA Sequencing
Findings for miR-493-5p in TCGA Dataset
TCGA dataset was queried to independently validate the find-
ings of the small RNA sequencing. All patients included in
TCGA cohort were diagnosed with HGSOC and underwent sur-
gery followed by platinum-based chemotherapy. miR-139-5p,
miR-493-5p, miR-378a-5p and miR-491-5p, miR-369-3p, and
miR-141-3p were queried for their impact on survival in
BRCA1- and BRCA2-mutated HGSOC using quartile cutoff to
segregate carcinomas with high, intermediary, and low miRNA
expression. (TCGA miRNA expression data were not available
for miR-3188 and miR-5000-3p). HGSOC with miRNA expres-
sion levels below 25% were classified as low expression,
HGSOC with levels between 25% and 75% quartile were classi-
fied as intermediary expression, and HGSOC with miRNA levels
above 75% quartile were classified as high expression.
Of the 6 miRNAs identified in the small RNA sequencing, only
miR-493-5p was associated with outcome in TCGA dataset.
Specifically, in resonance with the observations from the RNA
sequencing, overexpression of miR-493-5p (Figure 1C) was
associated with worse outcome after platinum chemotherapy
in BRCA2-mutated carcinomas of TCGA dataset, but not in
BRCA1-mutated carcinomas.We did not observe an association
between miR-139-5p, miR-378a-5p and miR-491-5p, miR-369-
3p, and miR-141-3p levels and survival outcome in either the
BRCA1-mutated or the BRCA2-mutated HGSOCs of TCGA da-
taset (Figure S1C).
To evaluate the impact of miR-493-5p on tumor regression, we
queried miR-493-5p expression levels in carcinomas classified
into 2 groups based on the amount of residual tumors detected
post-debulking surgery (group A: cases with no residual tumors
detected, 1–10 mm residual tumors; group B: cases with
11–20 mm and >20 mm residual tumors detected). We did not
observe a significant difference in miR-493-5p expression levelsCell Reports 23, 100–111, April 3, 2018 101
Figure 1. Expression of miR-493-5p Correlates with Platinum-Resistant/Refractory Disease Specifically in BRCA2 Mutant Ovarian
Carcinomas
(A) Volcano plot representing differentially expressed miRNAs in platinum-sensitive versus platinum-resistant/refractory carcinomas. x axis represents mean
difference in miRNA expression (sensitive versus resistant), and y axis represents ANOVA p value (log10).
(B) Overall survival (OS) for patients withBRCA1- orBRCA2-mutated ovarian carcinomas based on above or belowmedian expression values ofmiR-493-5p. Left
panel denotes overall survival forBRCA1-mutated tumors. Right panel denotes overall survival forBRCA2-mutated tumors. Statistical significance was assessed
by the log rank test.
(C) Progression-free survival (PFS) for patients with BRCA1- or BRCA2-mutated HGSOCs based on quartile cutoff expression values of miR-493-5p. Left panel
denotes progression-free survival for BRCA1-mutated carcinomas. Right panel denotes progression-free survival for BRCA2-mutated carcinomas. Statistical
significance was assessed by the log rank test.
For all panels, n.s. represents p value > 0.05, *p value < 0.05, **p value < 0.01, ***p value < 0.001, and ****p value < 0.0001. See also Figure S1.between the two groups. Furthermore, multivariate survival anal-
ysis with miR-493-5p expression levels and amount of tumor
detected post-surgery as covariates in BRCA2-mutated carci-
nomas showed significant impact of miR-493-5p expression
on survival but no association between disease-free survival
and the amount of residual tumor detected. In BRCA1-mutated
tumors, no significant association was observed with miR-493-
5p expression levels and amount of residual tumor (Figure S1D).
Taken together, the results from the small RNA sequencing and
TCGA dataset suggest that miR-493-5p may be a mediator of
platinum resistance in BRCA2-mutated ovarian carcinomas.
miR-493-5pMediates Resistance to PlatinumandPARPi
in BRCA2 Mutant, but Not BRCA1 Mutant, Models
In Vitro
We evaluated the impact of miR-493-5p on PARPi and plat-
inum sensitivity in a panel of patient-derived BRCA1-mutated
(COV362 and UWB1.289) and BRCA2-mutated ovarian cancer
cell lines (OVSAHO and Kuramochi) and in BRCA2 mutant
VU423 fibroblast cells. As shown in Figure 2A, overexpression
of miR-493-5p is associated with cisplatin and olaparib resis-
tance, causing significant increase in the half maximal inhibitory
concentration (IC50) for cisplatin and olaparib in BRCA2 mutant102 Cell Reports 23, 100–111, April 3, 2018OVSAHO, Kuramochi, and VU423 cells. miR-493-5p overex-
pression is also associated with resistance to PARPi rucaparib
and alkylating agent carboplatin in BRCA2 mutant VU423 cells
(Figure S2A). Conversely, in agreement with the small RNA
sequencing data and TCGA findings, overexpression of miR-
493-5p had no effect on cisplatin and olaparib sensitivity in
BRCA1-mutated COV362 and UWB1.289 cells (Figure 2B).
Additionally, antagonizing endogenous miR-493-5p significantly
sensitized BRCA2 mutant OVSAHO, Kuramochi, and VU423
cells to cisplatin and olaparib (Figure S2B).
miR-493-5p Is Upregulated in a Brca2-Mutated
Mammary Tumor Model with Acquired PARPi
Resistance In Vivo
To determine whether overexpression of miR-493-5p could be a
possible mechanism of acquired resistance in BRCA2-mutated
cancers, we utilized the unique genetically engineered mouse
(GEM) KB2P mouse model for Brca2-deficient breast cancer
(Jaspers et al., 2015; Jonkers et al., 2001). This model harbors
large intragenic deletion in Brca2; therefore, acquired resistance
to PARPis in this model cannot occur via secondary Brca2muta-
tions. Tumors from KB2P mouse donors were transplanted or-
thotopically into wild-type syngeneic mice, and when the tumor
Figure 2. Expression of miR-493-5p Causes PARPi and Platinum Resistance in BRCA2 Mutant Cells In Vitro and In Vivo
(A) Survival assays to examine the impact of miR-493-5p overexpression in BRCA2 mutant KURAMOCHI, OVSAHO, and VU423 cells exposed to the indicated
DNA-damaging agents.
(B) Survival assays to examine the impact of miR-493-5p overexpression in BRCA1 mutant COV362 and UWB1.289 cells exposed to the indicated DNA-
damaging agents.
(C) Schematic for KB2P (p53/ Brca2/ mouse model) PARPi intervention study.
(D) miR-493-5p expression levels in matched PARPi-naive and resistant KB2P p53/ Brca2/ mammary mouse models (derived from independent spon-
taneous tumor donors). Expression was normalized using U6SnRNA as reference.
For all panels, data are represented as mean ± SEM from three different experiments, n.s. represents p value > 0.05, *p value < 0.05, **p value < 0.01, ***p value <
0.001, and ****p value < 0.0001. See also Figure S2.reached a volume >200 mm3, mice were treated with the PARPi
AZD2461 for 28 consecutive days. Of note, PARPi AZD2461 is
not a P-glycoprotein (Pgp) substrate, and therefore, acquired
resistance to AZD2461 cannot be mediated by Pgp upregulation
(Oplustil O’Connor et al., 2016). After an initial phase of response,
the tumors eventually relapsed and were allowed to regrow to
100% volume, following which another treatment cycle was
started. Eventually, upon repeated exposure, mouse models
with acquired resistance to PARPi AZD2461 were generated.
Each untreated naive tumor had either one or more matched
resistant counterparts (Figure 2C). Out of 40 resistant tumormodels generated from 19 untreated naive tumors, we observed
a statistically significant increase in miR-493-5p levels in 13 of
them (32.5%; 90% confidence interval [CI]: 20.4%–40.6%;
Figure 2D).
Microarray Profiling to Identify Gene Targets of
miR-493-5p
Given the potential of miRNAs to regulate multiple mRNA tran-
scripts, we utilized an unbiased approach to identify gene
targets for miR-493-5p. Accordingly, we used the HTA2.0
(Affymetrix) microarray platform to profile whole transcriptomeCell Reports 23, 100–111, April 3, 2018 103
Figure 3. miR-493-5p Significantly Downregulates Expression of Multiple Genes Involved in Genomic Stability
(A) Volcano plot depicting differentially expressed genes in control-miR versus miR-493-5p-overexpressing Kuramochi cells. x axis represents log2 expression
fold change in control-miR versus miR-493-5p-mimic-transfected cells, and the y axis represents ANOVA p value (log10).
(B) Quadrant-based segregation to identify genes that are significantly differentially expressed in themicroarray and significantly correlate to levels ofmiR-493-5p
in BRCA2-mutated carcinomas in the TCGA dataset. Highlighted quadrant four represents 245 genes that are significantly downregulated in the microarray and
correlate significantly to miR-493-5p levels in the TCGA cohort of 34 BRCA2-mutated tumors.
(C) Quantification of protein levels in miR-493-5p-transfected cells normalized to control-miR-transfected cells.
For (C), data are represented as mean ± SEM from two different experiments, n.s. represents p value > 0.05, *p value < 0.05, **p value < 0.01, ***p value < 0.001,
and ****p value < 0.0001. See also Figure S3.changes in BRCA2-mutated Kuramochi cells, transfected with
either control-miRNA or miR-493-5p mimics (Figure 3A). Com-
parison was performed between gene expression levels in
control versus miR-493-5p transfected cells, with a statistical
significance criterion of p value < 0.05 and a false discovery
rate cutoff of <0.2. We performed gene set enrichment anal-
ysis (GSEA) on the significant hits and identified several path-
ways that play a key role in DNA replication and repair among
the top hits to be downregulated in miR-493-5p-overexpress-
ing cells (Table S1). To better define miR-493-5p-responsive
pathways, we performed miRNA-mRNA correlation analysis
for BRCA2-mutated tumors in TCGA dataset and identified
256 genes (Figure 3B) that were both (1) significantly overex-
pressed in control-miRNA transfected compared to miR-493-104 Cell Reports 23, 100–111, April 3, 20185p mimic transfected Kuramochi cells and (2) inversely corre-
lated with miR-493-5p levels among the BRCA2-mutated
carcinomas in the TCGA dataset. A few genes that fit these
criteria (FEN1, SSRP1, and EME1) have been implicated in
maintenance of genome stability. However, there were also
several genes (MRE11, BLM, EXO1, and CHD4) that had a
very striking difference in our transcriptomic analysis but did
not meet the statistical significance cutoff for inverse correla-
tion with miR-493-5p in TCGA (Figure S3). To delineate the
mechanism behind the observed decrease in transcript levels,
we queried publicly available databases and identified miRNA
binding sites for these genes (Table 1). Subsequently, we as-
sessed the impact of miR-493-5p on the protein levels of all
these genes (SSRP1, FEN1, EXO1, RNASEH2A, BLM, and
Table 1. miR-493-5p Binding Sites in the Genomic Sequences of the Indicated Genes Predicted Using the RNA 22 Version 2.0
Algorithm
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A G A A G A A G A A A U A C A C A U G C U C A U BLMCHD4) in three BRCA2 mutant cell lines. Consistent with our
mRNA analysis, we observed a decrease in protein levels of
these factors in multiple BRCA2 mutant cell lines transfected
with the miR-493-5p mimic (Figure 3C). Having established
the impact of miR-493-5p on these transcripts, next we
decided to investigate the relevance of our identified targets
by querying the impact of miR-493-5p on different repair path-
ways where these factors are known to play an important role.
miR-493-5p Decreases SSA in BRCA2-Mutated Cells
and Does Not Rescue HRR
The primary mechanism by which BRCA mutant ovarian carci-
nomas develop platinum or PARPi resistance is by the restora-
tion of HRR (Norquist et al., 2011; Sakai et al., 2008, 2009).
Additionally, a recent study (Feng and Jasin, 2017) has used sep-
aration-of-function BRCA2 mutants to demonstrate that the
impact of BRCA2 on cell viability is primarily mediated by it func-
tion in HRR and not replication fork stability. Therefore, we
explored the impact of miR-493-5p on HRR using the HDR re-
porter substrate (DR-GFP) reporter assay. BRCA2 knockdown
in the DR-GFP system showed a decrease in HRR efficiency
as expected; however, we did not observe a rescue in HRR
upon overexpression of miR-493-5p after BRCA2 knockdown(Figure 4A). As an additional readout for HRR, we performed
Rad51 foci formation assay in BRCA1/2-wild-type U2OS cells
(Figure 4B) and in BRCA2 mutant VU423 and Kuramochi cells
(Figures S4A and S4B). As with the results obtained with the
DR-GFP system, overexpression of miR-493-5p caused a mod-
erate decrease in Rad51 foci in wild-type U2OS cells but did not
rescueHRR inBRCA2-mutated VU423 and Kuramochi cells. The
SSA repair pathway is distinct as it distinguishes BRCA1 and
BRCA2 mutant cells. BRCA1 mutant cells exhibit diminished
HRR and SSA, whereas BRCA2 mutant cells have impaired
HHR but a hyperactive SSA repair pathway, which is responsible
for increased chromosomal aberrations in these cells (Stark
et al., 2004). To study SSA, we utilized a previously reported
SSA reporter pathway system (Bennardo et al., 2008; Stark
et al., 2004). In agreement with published reports, we observed
a significant escalation in SSA upon BRCA2 loss (Figure 4A).
However, in cells with silenced BRCA2, overexpression of
miR-493-5p was associated with a significant decrease in SSA
(Figure 4A). As an additional readout for SSA, we created a stable
VU423 cell line expressing mCherry-tagged Rad52. In concor-
dance with the results in reporter cells, we also observed a sig-
nificant decrease in Rad52 foci upon overexpression of miR-
493-5p (Figure 4C). We also assessed whether miR-493-5pCell Reports 23, 100–111, April 3, 2018 105
Figure 4. miR-493-5p Has an Impact on SSA, DNA Replication Fork Stability in BRCA2 Mutant, or Depleted Cells
(A) DR-GFP, SA-GFP, EJ-2, and EJ-5 assay in U2OS cells transfected with indicated siRNA or miRNA.
(B) Quantification of Rad51 foci dynamics in U2OS cells transfected with the indicated miRNA.
(C) Quantification of Rad52 foci dynamics in VU423 cells stably expressing mCherry-Rad52 reporter transfected with the indicated miRNA.
(D) Quantification of Idu/Cldu lengths in Kuramochi cells transfected with control-miR or miR-493-5p mimics with or without hydroxyurea treatment (left panel).
Schematic of labeling cells with Cldu and Idu to study replication fork degradation (right panel) is shown.
For all panels, data are represented as mean ± SEM from three different experiments, n.s. represents p value > 0.05, *p value < 0.05, **p value < 0.01, ***p value <
0.001, and ****p value < 0.0001. See also Figure S4.affects the other DSB repair pathways, C-NHEJ and alt-EJ, using
the EJ5 and EJ2 reporter system, respectively (Figure 4A).
BRCA2 silencing did not have a significant impact on C-NHEJ
or alt-EJ. We did not observe a change in alt-EJ in BRCA2-
silenced cells overexpressing miR-493-5p. However, we did
observe a modest but statistically significant increase in total
NHEJ measured by the EJ5 reporter assay system in BRCA2-
silenced cells overexpressing miR-493-5p, although there was
no difference compared to non-BRCA2-silenced cells (Fig-
ure 4A). The decrease in HRR and SSA by expression of miR-
493-5p is consistent with its impact on the DNA end resection
machinery (EXO1,MRE11, and BLM). These results led us to hy-
pothesize that miR-493-5p might potentiate PARPi and platinum
resistance in BRCA2 mutant cells, not by restoring HRR but by
muting the otherwise hyperactive SSA pathway and promoting
repair by NHEJ.106 Cell Reports 23, 100–111, April 3, 2018miR-493-5p Stabilizes Replication Fork in BRCA2
Mutant Cells
Stabilization of DNA replication fork has recently emerged as a
mechanism of PARPi and platinum resistance in BRCA2 mutant
cells. CHD4 (Guillemette et al., 2015), MRE11 (Ding et al., 2016;
Schlacher et al., 2011), and EXO1 (Lemac¸on et al., 2017) are
factors that contribute to destabilizing the replication fork in
BRCA2 mutant cells and are recruited/stabilized at the fork by
PTIP (Ray Chaudhuri et al., 2016). It is worth noting that silencing
PTIP causes resistance to olaparib and cisplatin in Kuramochi
and OVSAHO cells at a scale comparable to the impact of
miR-493-5p (Figure S4C). Because top hits from our transcrip-
tomic analysis include nucleases, in particular MRE11 and
EXO1, we proceeded to quantify the effect of miR-493-5p on
replication fork stability using DNA fiber analysis. To study repli-
cation fork dynamics after overexpression of miR-493-5p in
BRCA2-mutated Kuramochi cells, cells were labeled with Cldu
for 1.5 hr and Idu for 2 hr followed by hydroxyurea (HU) exposure
for 3 hr. In BRCA2 mutant Kuramochi cells treated with control
miRNA, HU significantly decreased the ratio of Idu/Cldu consis-
tent with shortening of the Idu replication tract (Figure 4D). How-
ever, in Kuramochi cells overexpressing miR-493-5p, HU expo-
sure did not cause any significant change in Idu/Cldu ratio,
suggesting a potential role for miR-493-5p in regulating genes
responsible for replication fork protection in BRCA2-mutated
cells (Figure 4D). Results from ourmicroarray profiling (Figure 3A)
and DNA fiber analysis provide strong evidence that PARPi
and platinum resistance induced by miR-493-5p in BRCA2
mutant cells may be a result of DNA replication fork stabilization
achieved through downregulation of MRE11 and CHD4.
miR-493-5p May Impact Multiple Genome-Stabilizing
Pathways
As stated above, top hits from our bioinformatics analysis iden-
tified targets for miR-493-5p like FEN1, SSRP1, and RNASEH2A
that are known to play a role in R-loop processing and ribonucle-
otide excision repair (RER) pathway (Figure 5A; Herrera-Moyano
et al., 2014; Teasley et al., 2015; Williams et al., 2016) To inves-
tigate the impact of miR-493-5p on R-loop processing, we used
a monoclonal S9.6 antibody that specifically detects RNA-DNA
hybrids. We measured S9.6 signal intensity in miR-493-5p-over-
expressing BRCA2-mutated VU423 cells and detected a signifi-
cant increase in R-loops (Figure 5B), which was abolished upon
transient overexpression of GFP-tagged RNaseH1.
To determine whether RER pathway members identified
from our analysis play a role in mediating chemo-resistance in
BRCA2 mutant cells, we silenced RNASEH2A, SSRP1, or
FEN1 in BRCA2 mutant cells. Loss of these genes induces
PARPi and platinum resistance (Figure 5C). Finally, we analyzed
the correlation of RNASEH2A, FEN1, and SSRP1 expression
with disease-free survival after platinum chemotherapy in
BRCA2mutant carcinomas in TCGA. Consistent with the notion
that miR-493-5p-mediated suppression of these factors pro-
motes platinum resistance in BRCA2 mutant carcinomas, we
observe a striking inverse correlation of RNASEH2A, FEN1,
and SSRP1 with outcome after platinum chemotherapy only in
BRCA2 mutant carcinomas and not in BRCA1 mutant carci-
nomas (Figures 5D and S5A). Together, these results suggest
that miR-493-5p may mediate response to PARPi and plat-
inum-based drugs in BRCA2-mutated tumors by regulating
genes that play an important role in diverse repair pathways.
DISCUSSION
We report miR-493-5p as a mediator of platinum and PARPi
resistance in BRCA2-mutated ovarian carcinoma. mir-493-5p
has been previously implicated in the process of carcinogenesis
by regulating a number of target genes, including c-MET, EGFR
(Wang et al., 2017), integrin subunit beta 1 (ITGB1) (Liang et al.,
2017), and fucosyltransferase IV (FUT4) (Zhao et al., 2016) in
various tumor types, including breast, prostate, and lung can-
cers. However, no previous implication of miR-493-5p in DNA
repair or responsiveness to chemotherapy has been reported.
We identified miR-493-5p by next-generation sequencing ofsmall RNAs extracted from primary and recurrent BRCA1/2-
mutated ovarian carcinomas, which was then validated in the
TCGA ovarian cancer dataset (Cancer Genome Atlas Research
Network, 2011). None of these tumors harbored secondary
BRCA1/2 mutations, suggesting that the association between
miR-493-5p and platinum resistance could not have been
confounded by presence of secondary BRCA1/2 mutations. In
addition to the findings from patient tumor samples, miR-493-
5p conferred platinum and PARPi resistance inBRCA2-mutated,
but not BRCA1-mutated, cell lines in vitro and was found to
be significantly overexpressed in approximately one-third of
Brca2-deficient KB2P mammary tumor models (13 of 40
resistant models) with acquired in vivo resistance to PARPi
AZD2461 compared to paired naive untreated tumors. It is
important to underscore that secondary Brca2 mutations or
Pgp overexpression cannot explain the acquired resistance of
KB2Pmodel to AZD2461 because the KB2Pmodel harbors bial-
lelic deletion in Brca2 and PARPi AZD2461 is not a P-glycopro-
tein (Pgp) substrate.
Mechanistically, to identify clinically relevant gene targets of
miR-493-5p, we performed gene expression profiling to identify
genes that were significantly downregulated in BRCA2-mutated
ovarian cancer cells transfected with miR-493-5p. The downre-
gulated transcripts included many key genes required for
genome stability, and several of these inversely correlated with
expression of miR-493-5p in BRCA2-mutated ovarian carci-
nomas from TCGA dataset, thereby ensuring the clinical
relevance of this interaction. Diminished transcript levels do
not always lead to significant decrease in protein; therefore,
we validated by immunoblot that indeed miR-493-5p downregu-
lates the expression of these factors involved in DNA repair/repli-
cation and genomic stability. This approach identified several
miR-493-5p targets that are involved in pathways that are rele-
vant to the biology of BRCA2-mutated carcinomas as well as
the development of platinum and PARPi resistance.
Stabilizing the replication fork is a recently identified mecha-
nism of platinum and PARPi resistance in BRCA2-mutated car-
cinomas (Ray Chaudhuri et al., 2016). Beyond their role in DSB
repair via HRR, BRCA1 and BRCA2 occupy an important role
in limiting access of nucleases (such asMRE11) to single-strand
DNA at stalled replication forks, thereby leading to replication
fork protection. Recently, loss of PTIP, CHD4, and EZH2 have
been identified as a mechanism of resistance in BRCA2-defi-
cient cells (Ding et al., 2016; Guillemette et al., 2015; Ray Chaud-
huri et al., 2016; Rondinelli et al., 2017). Specifically, deficiency in
PTIP and CHD4 impedes recruitment of MRE11, thereby pro-
tecting stalled replication forks from nucleolytic degradation in
BRCA2 mutant cells. Two clinically relevant questions that
emerge from these studies are (1) are these factors downregu-
lated in BRCA2 mutant carcinomas? (2) What is the mechanism
by which the factors are suppressed? Here, we observed that
miR-493-5p significantly downregulated MRE11, CHD4, and
another nuclease EXO1 in BRCA2 mutant cells. Most impor-
tantly, consistent with these results, miR-493-5p preserved repli-
cation fork stability in BRCA2-mutated ovarian cancer cells.
We also show that miR-493-5p plays a role in regulating DSB
repair pathway choice in BRCA2 mutant cells. miR-493-5p
decreased SSA and in consonant also significantly decreasedCell Reports 23, 100–111, April 3, 2018 107
Figure 5. miR-493-5p Has an Impact on Pathways Regulating R-Loop Processing and Ribonucleotide Excision Repair Pathway
(A) Plot showing correlation of miR-493-5p with different pathways.
(B) Quantification of R-loops measured as S9.6 intensity in BRCA2 mutant VU423 cells transfected with control-miR or miR-493-5p post-transfection with
RNaseH1-GFP.
(C) Survival assays to assess the impact of BRCA2 mutant Kuramochi, OVSAHO, and VU423 cells transfected with the indicated siRNA and treated with the
indicated DNA-damaging agents.
(D) Progression-free survival for BRCA2-mutated HGSOC in the TCGA dataset segregated based on the median expression levels of RNASEH2A, SSRP1, and
FEN1. Statistical significance was assessed by the log rank test.
For Figures 5B and 5C, data are represented as mean ± SEM from three different experiments, n.s. represents p value > 0.05, *p value < 0.05, **p value < 0.01,
***p value < 0.001, and ****p value < 0.0001. See also Figure S5.levels of BLM and EXO1 along withMRE11, which are key actors
in DNA end resection, a critical step in SSA. Additionally, miR-
493-5p did not rescue HRR, thereby eliminating restoration of
HRR as a possible explanation of the observed platinum and
PARPi resistance. These observations distinctly indicate that
miR-493-5p impacts DNA repair pathway choice in BRCA2
mutant cells and may mediate platinum and PARPi resistance
by suppression of the highly mutagenic and genome-destabiliz-
ing SSA, which is otherwise hyperactive in BRCA2 mutant cells.
Finally, our analysis identified RNASEH2A, FEN1, and SSRP1
as miR-493-5p targets; these genes are known to be implicated
in multiple genome-stabilizing pathways, including the degrada-108 Cell Reports 23, 100–111, April 3, 2018tion of transcriptionally generated R-loops (Herrera-Moyano
et al., 2014; Teasley et al., 2015) and RER pathway. R-loops
are an established source of genome instability and a potential
driver of tumorigenesis (Aguilera and Garcı´a-Muse, 2012; Agui-
lera and Go´mez-Gonza´lez, 2017; Santos-Pereira and Aguilera,
2015; Sollier and Cimprich, 2015). The precise molecular
mechanisms by which R-loops promote tumorigenesis remain
unclear. A genome-wide examination of R-loop dynamics in
different cell types from BRCA1 mutation carriers revealed
BRCA1-mutation-associated R-loops preferentially accumu-
late in luminal epithelial cells and at specific genomic loci
leading to tumorigenesis (Zhang et al., 2017). Furthermore, in
BRCA1-deficient carcinomas, there is a significant enrichment of
mutations at precise locations whereBRCA1 is predicted to sup-
press R-loops (Hatchi et al., 2015). BRCA2 also plays a key role
in removal of R-loops that are formed in transcriptionally active
regions of the genome (Bhatia et al., 2014). So far, there is no in-
formation on whether R-loops impact response of BRCA2-defi-
cient carcinomas to platinum drugs and PARPis. Based on our
results, we speculate that an increase in R-loops might be a
contributing factor to the chemo-resistance of BRCA2-deficient
carcinomas.
Although both BRCA1 and BRCA2 are involved in HRR and
loss of these factors confers PARPi sensitivity, expression of
miR-493-5p induces platinum and PARPi resistance exclusively
in BRCA2-mutated cells. It is noteworthy that the genomic land-
scape of BRCA1 and BRCA2 tumors is very different with very
distinct chromosomal aberrations and mutational signatures
(Nik-Zainal et al., 2016). Therefore, it is conceivable that, even
if miR-493-5p targets the same pathways in BRCA1mutant car-
cinomas, it doesn’t cause platinum and PARPi resistance due to
other genetic/epigenetic differences with BRCA2 mutant carci-
nomas. In conclusion, we report miR-493-5p as a mediator of
platinum andPARPi resistance inBRCA2-mutated ovarian carci-
nomas. Our data suggest that miR-493-5pmediates chemother-
apeutic response by targeting several genes in pathways that
play an important role in the maintenance of genome stability.
Our study highlights a previously unrecognized role for miR-
493-5p as a potential biomarker of responsiveness to platinum
and PARPis as well as a target for reversing platinum and PARPi
resistance in BRCA2-mutated ovarian carcinomas.
EXPERIMENTAL PROCEDURES
miRNA Profiling and Survival Analysis
Exiqon miRNA profiling was used to identify miRNAs that are differentially ex-
pressed in 38 BRCA1/2-mutated carcinomas with known response to plat-
inum therapy obtained from the University of Washington Gynecologic
Oncology Tissue Bank, in which tissues are obtained from patients undergoing
surgery for primary or recurrent ovarian carcinoma who provide informed con-
sent according to an institutional review board (IRB)-approved protocol. These
carcinomas were confirmed to not harbor BRCA1/2 reversion mutations by
sequencing. Normalized sequencing data counts for 953 miRNAs were avail-
able from Exiqon. Any miRNAs that were not detected in more than 19 of the
carcinomas were not included in the final analysis. Expression values were
standardized, following which miRNA levels were queried in refractory versus
sensitive tumors. Independent samples t test with p value significance <0.05
was used as a statistical cutoff. 48 miRNAs were differentially expressed in re-
fractory versus sensitive carcinomas (both directions). Overall survival data
were queried for the available carcinomas, and log rank (Mantel-Cox) p value <
0.05 was used as a statistical cutoff to identify miRNAs that have an effect on
overall survival. We queried overall survival data for 38 carcinomas based on
median cutoff of miRNA expression. 8 miRNAs significantly affect overall sur-
vival in 38BRCA1/2-mutated tumors. Next, we queried the survival analysis for
the 8miRNAs identified to be differentially expressed and causing a significant
effect on overall survival in BRCA1/2-mutated carcinomas in 2 subgroups:
BRCA1-mutated carcinomas and BRCA2-mutated carcinomas. We utilized
the TCGA cohort for validating our results observed in the University of Wash-
ington cohort. We queried the survival analysis for the 8 miRNA hits in 38
BRCA1-mutated carcinomas and 34 BRCA2-mutated carcinomas.
Cell Survival Assays
For assessing cellular toxicity, cells were transfected with the indicated small
interfering RNA (siRNA) or miRNA for 48 hr before plating cells into 96-wellplates. The next day, DNA-damaging agents were added at the indicated con-
centrations. Cells were incubated with the drug containing media for 5 or
6 days before media was removed and replaced with drug-free media. Cells
were incubated in drug-free media for 3 days before viability was measured
using Cell-titer Glo reagent and assayed using a luminescence plate reader.
Untreated and treated conditions were repeated in triplicates for each exper-
iment, and each experiment was repeated at least three times. Viability for
each drug concentration was normalized using untreated condition. Graphs
represent percentage of surviving cells for each condition ± SEM.
mir-493-5p Levels in KB2P Tumor Models
RNA extracted from 19 naive and 40 resistant KB2P p53/ Brca2/mam-
mary tumor models using Trizol reagent (Invitrogen) was reverse transcribed
using Universal cDNA synthesis kit II (Exiqon). Resulting cDNA was used to
query miR-493-5p levels using ExiLENT SYBR Green master mix and LNA
qPCR primers designed to accurately detect mmu-miR-493-5p in an Applied
Biosystems qPCRmachine. All reagents were used according tomanufacturer
instructions. miR-493-5p expression level was normalized to expression of U6
small nuclear RNA (snRNA) using the DCt method. Graphs represent expres-
sion values of miR-493-5p for each resistant tumor relative to miR-493-5p
levels for its naive tumor counterpart and are indicated as average ± SEM.
Each reaction had at least 4 replicates. LNA qPCR primer target sequence is
as described on Exiqon’s website.
The U6snRNA target sequence (targets hsa, mmu U6snRNA) is as follows:
GUGCUCGCUUCGGCAGCACAUAUACUAAAAUUGGAACGAUACAGAGAA
GAUUAGCAUGGCCCCUGCGCAAGGAUGACACGCAAAUUCGUGAAGCGU
UCCAUAUUUUU.
The miR-493-5p target sequence (targets mmu miR-493-5p) is as follows:
UUGUACAUGGUAGGCUUUC.
Microarray Profiling and Data Analysis
RNAwas extracted fromBRCA2mutant Kuramochi cells transfected twicewith
either control-miR or miR-493-5p and submitted for whole-transcriptome
profiling to theMolecularBiologyCoreFacilitiesatDana-FarberCancer Institute.
Affymetrix Human Transcriptome Array (HTA) 2.0 platform was used for quanti-
fication of transcripts. Pre-processing of Affymetrix CEL fileswas performedus-
ing ExpressionConsole software application (Affymetrix) using the robustmulti-
chipanalysis (RMA)algorithm,whichperformsbackgroundadjustment,quantile
normalization, andprobe-level summarization. A total of 67,528 transcriptswere
detected in the microarray, of which 44,699 were probed in coding regions of
genomeand22,829wereprobed innon-coding regionsofgenome.Foldchange
(linear and log 2) for each transcript detected was calculated for control versus
miR-493-5p-transfected cells from raw values. For the purpose of our analysis,
we focusedon transcripts queried in the coding regions of the genome. (ANOVA
pvalue<0.05and falsediscovery rate [FDR]pvalue<0.20 [Benajmini-Hochberg
method] were used for statistical significance). For every gene that passed the
statistical significance tests, publicly available TCGAmRNA expressionZ score
data along with themicroRNA expression Z scores for miR-493-5p were down-
loaded from http://cBioportal.org. Clinical characteristics for carcinomas in the
TCGA dataset along with BRCA1 and BRCA2 mutational information was also
downloaded from http://cBioportal.org. Thirty-four carcinomas harboring a
BRCA2 mutation were isolated from the cohort (two tumors: TCGA-13-1512-
01 and TCGA-23-1026-01 have both a BRCA1 and BRCA2 mutation and are
considered to be hyper-mutated and not included in the analysis). Non-para-
metricSpearmancorrelationcoefficient andone-tailedp value (95%confidence
interval) was calculated for each gene and miR-493-5p pair for the 34 BRCA2-
mutated samples. Quadrant-based scatterplot was created by plotting log2
fold change (x axis; control versusmiR493 transfected) against Spearman r cor-
relation coefficient values for genes with a significant correlation to miR-493-5p
in the TCGA dataset. Each quadrant (labeled in Figure 3B) was classified based
on thedirectionandmagnitudeof changeor correlation for eachgene.All neces-
sary calculations were performed using Microsoft Excel, SPSS Statistics v24,
and Graph Pad Prism v7.0.c.
Reporter Assays
HRR, SSA, alt-EJ, and total NHEJ were measured using U2OS-based reporter
assay systems as described previously. Briefly, cells were seeded in 6-wellCell Reports 23, 100–111, April 3, 2018 109
plates and reverse transfected with the indicated siRNA, miRNA, or combina-
tion of both. 24 hr after transfection, cells were incubated with Isce1 adeno-
virus for 1 hr in FBS-free media, following which cells are incubated for 48 hr
in FBS-containingmedia before harvesting for flow cytometry analysis. Activity
of each reporter systemwas determined by fluorescence-activated cell sorting
(FACS) quantification of GFP-positive cells. Each graph represents relative
mean values ± SEM for each condition calculated by normalizing each condi-
tion to control transfected cells. Each experiment was repeated at least three
times.
Cell Line Construction
pEF1a-mcherry-Rad52 plasmid was kindly provided by Dr. Galit Lahav. Stable
cell line expressing the plasmid was generated by transfecting VU423 cells us-
ing Fugene 6 followed by selection in hygromycin-containing media.
Immunofluorescence
For Rad51 foci experiments, cells were transfected with indicated siRNA or
miRNA or combination of both 48 hr before irradiation 5 Gy (gamma-IR). Cells
were fixed 6 hr post-irradiation with 1% paraformaldehyde and 0.5% Triton
X-100 for 30 min. Bovine serum albmin-Triton X-100-goat serum (BTG) buffer
containing 1mg/mL BSA, 0.1% Triton X-100, 3% goat serum, and 1mMEDTA
in PBS was used for blocking and to dilute primary (1) and secondary (2) an-
tibodies. Coverslips containing cells were blocked in BTG buffer for 1 hr (room
temperature), followed by overnight incubation in 1 antibody (4C), three PBS
washes, 1-hr incubation with 2 antibody (room temperature), and three
washes. Coverslips were mounted with DAPI-containing mounting media
(Southern Biotech). Number of foci per cell was quantified using publicly avail-
able cell image analysis software Cell Profiler (Broad Institute). More than
200 cells were imaged and quantified for number of foci for each condition.
Graphs represent the raw values for number of foci for each condition. Error
bars represented are SEM for each condition.
DNA Fiber Assay
DNA fiber analysis was performed as described before (Nieminuszczy et al.,
2016). Briefly, BRCA2 mutant Kuramochi cells were transfected with either
control-miR or miR-493-5p for 48 hr followed by incubation with chlorodeox-
yuridine (Cldu) for 1.5 hr followed by incubation with iododeoxyuridine (Idu) for
2 hr followed by treatment with either DMSO or 4 mM hydroxyurea for 3 hr.
Cells were spotted on a slide followed by lysis with lysis buffer (200 mM
Tris-HCl [pH 5.5], 50 mM EDTA, and 0.5% SDS), followed by 120-min incuba-
tion with 2.5 M hydrochloric acid. After three washes in water, slides are pro-
cessed for immunofluorescence. Slides were incubated with blocking buffer
(1% BSA in PBS) for 1 hr at room temperature followed by incubation with pri-
mary antibody for 1 hr at 37C. Slides were washed three times in PBS fol-
lowed by incubation with secondary antibody for 1 hr at 37C. Coverslips
were mounted on slides with DAPI-containing mounting media (Southern
Biotech). At least 100 fibers were counted per condition. Images were
analyzed using ImageJ software. Ratio of Idu fiber length/Cldu fiber length
was used as a measure of fiber degradation. Primary antibodies used for
this experiment were as follows: rat anti-bromodeoxyuridine (BrdU) specific
to Cldu (Abcam; ab6326; 1:125) and mouse anti-BrdU specific to Idu (BD Bio-
sciences; 347580; 1:50). Secondary antibodies used for this experiment were
as follows: goat anti-rat immunoglobulin G (IgG) Alexa 488 (Life Technologies;
A-11006; 1:250) and donkey anti-mouse IgG Alexa Fluor 594 (Life Technolo-
gies; A-21203; 1:250).
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